David Eichenbaum, MD and Riad Sherif, MD, CEO of Oculis will present the updates with additional info on topline results from the ACUITY Phase 2 trial of OCS-05 for the treatment of acute optic neuritis (AON).

AEYE Health will attend the American Academy of Ophthalmology (AAO) Annual Meeting, from October 18-21 in Chicago.

A recent paper reveals increasing rates of diabetic retinopathy in young patients with diabetes, sparking concerns over inadequate screening and management, especially among Black and Hispanic youths.

This patented technology is designed to enhance the light sensitivity of a multi-characteristic opsin developed by Nanoscope as a gene therapy.

The European Association for Vision and Eye Research 27th EVER Congress will be held in Valencia, Spain, November 3 – 5, 2024.

The event will focus on UNITY’s ongoing Phase 2b ASPIRE study, which is evaluating foselutoclax (UBX1325) head-to-head against aflibercept in DME.

Applied Science, Inc. (ASI) is expanding its AdaptivMD chronic care workflow technology

The American Academy of Ophthalmology 2024 annual meeting features key lectures and award sessions, highlighting advancements in ophthalmology from leading experts across the field.

According to the company, the platform accompanies the launch of Qdata Retinitis Pigmentosa for life sciences and the development of Practice Insights for clinicians.

According to the company, MCO-010 is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration in advanced retinitis pigmentosa (RP), irrespective of gene mutation.

The Eye Care Network adds a longstanding, CME-certified conference to its live event programming

American Academy of Ophthalmology offers in-person and virtual options for annual meeting, Subspecialty Day.

Ten of the institute's ophthalmologists will present their work in more than 20 sessions with a wide range of topics

Tinlarebant is an oral therapy designed to reduce the accumulation of vitamin A based toxins that cause retinal disease.

Shruti Sharma, PhD, and a team from the MCG Center for Biotechnology and Genomic Medicine, hope to focus in on a new treatment pathway for diabetic retinopathy.

According to the company, the axitinib injectable suspension achieved all primary and secondary outcomes and maintained stable visual acuity and anatomical control over 9 months. There were no ocular or treatment-related serious adverse events.

Everads suprachoroidal delivery technology is designed to enable safe and effective in-office delivery of therapies to the choroidal and retinal tissues via the suprachoroidal space.

A new study described the underlying defect responsible for development of AMD and related macular dystrophies (MDs).

A team of researchers at Arizona State University has developed tools to aid in the diagnosis of myopic maculopathy.

The investigators undertook a study in which they retrospectively evaluated the presence and amount of small HRF in the eyes of patients with different macular atrophic phenotypes.

In a study, a team of UCLA investigators detail a deep-learning model pre-trained on 2D scans that accurately predicts disease-risk factors from 3D medical-scan modalities.

Marketed as Triesence, it is a preservative-free synthetic corticosteroid that is approved by the FDA for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids.

The award from the National Institutes of Health will enable a team of researchers to investigate Alzheimer and Parkinson progression through the eye.